• Questions? +1 (732) 747-1007
  • ir@americancryostem.com
  • Physicians
  • Licensing & Partners
American CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell Therapy
  • SERVICES
    • HOW IT WORKS
    • COSMETIC CRYO-FAT
    • ADULT STEM CELLS
  • PRODUCTS
    • TISSUE HARVESTING SYSTEM
    • STEM CELL MEDIAS
    • STEM CELL LINES
  • OUR SCIENCE
    • LONG COVID CLINICAL TRIAL
  • INVESTORS
    • ABOUT US
    • STOCK INFORMATION
    • PRESS RELEASES
    • OUR LEADERSHIP
    • LICENSING PARTNERS
  • NEWS
  • CONTACT

Personal Cell Sciences U Autologous Skin Care Listed on Forbes Top 10 Fashion and Beauty Startups for 2012

December 4, 2012

EATONTOWN, N.J., Dec. 4, 2012 (GLOBE NEWSWIRE) — American CryoStem Corporation (OTCQB:CRYO) is pleased to announce that Personal Cell Sciences (PCS), U Autologous Skin Care products have been listed on Forbes.com “Top 10 Fashion and Beauty Startups for 2012” released on November 27, 2012.

These cutting edge innovative products were developed by PCS, through a previously announced manufacturing and processing collaboration between American CryoStem and Personal Cell Sciences. To create the U-Autologous product formulation, the customers Adipose Tissue (fat) is collected through a participating physician using American CryoStem’s proprietary, adipose tissue collection system and processed into stem cells according to CRYO’s FDA compliant Standard Operating Procedures (SOP’s).

Additionally, under the agreement with PCS, CRYO utilizes its patented animal-free media to culture an individual’s stem cells to create the key ingredient in the PCS anti-aging formulation, Autokine-CMTM, which contains the individual’s proteins, growth factors and cytokines collected from their Adipose Derived Stem Cells.

“We are truly excited that the industry recognized our cutting edge science and innovative methodologies. The positive feedback we have received since the launch of the PCS, U-Autologous this year has reinforced the desire for personalized adult stem cell based products and services. We look forward to an excellent 2013 as the PCS brand begins to build awareness throughout the industry as the leading science based adult stem cell skin care company,” stated John DiFolco, Director of Marketing for PCS.

“American CryoStem provides the highest quality tissue collection, processing, storage and cellular expansion services available today. Through the continued efforts of our scientific staff and the use of our patented animal free cell culture products and processing methods we have been able to support the manufacturing needs of truly unique companies like PCS,” stated Anthony Dudzinski COO of American CryoStem Corporation. “We look forward to expanding our R&D and manufacturing partnerships with other companies participating in the Life Sciences and Regenerative Medicine Industry.”

About American CryoStem: American CryoStem Corporation (OTCQB:CRYO) is a leading biotech company focused on marketing its clinical processing services and patented products for Adipose Tissue (fat) and Adipose Derived Adult Stem Cells. Our clinical tissue processing, patented cell culture media products and tissue storage platform supports cosmetic and Regenerative Medicine applications being developed globally. The Company provides high quality, clinically processed viable cells, while at the same time developing cutting edge applications, therapies, patented laboratory products and services for consumer and commercial applications.

About Personal Cell Sciences: www.personalcellsciences.com

Investor Relations Contact:
American CryoStem Corporation
732-747-1007

www.americancryostem.com

Share

Related posts

January 6, 2023

American CryoStem Announces FDA Approval of IND to Commence Phase I Clinical Trial for Long COVID/Post-Acute Sequelae of SARS-CoV-2 (PASC)


Read more
December 22, 2022

American CryoStem Announces the Addition of Agustin Legido, MD, PhD, MBA to its Advisory Board


Read more
March 4, 2022

American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)


Read more

About American CryoStem Corporation

American CryoStem Corporation (OTC:CRYO), is a clinical-stage biotechnology company, global licensor and a pioneer in autologous (one’s own) cellular processing and therapies. The Company's centralized laboratory model and patented foundational “CryoStem Platform” is a best-in-class, end-to-end cellular therapy solution to treat injuries, disorders and chronic diseases through a single adipose-tissue (fat) harvest and ATCELLBank™ cryopreservation. We are dedicated to helping the world’s physicians, hospitals, and clinics improve clinical outcomes by developing and delivering effective leading-edge stem cell therapies that improve patient health and quality of life.

© 2021 American CryoStem Corporation | A Publicly Traded Company (CRYO)
  • Physicians
  • Licensing & Partners